Topical solutions for the treatment of nasal symptoms in the...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/573 (2006.01) A61P 27/14 (2006.01) A61P 31/12 (2006.01)

Patent

CA 2361345

Common cold is a viral infection resulting predominantly in inflammation of the nasal mucosa. The most prevalent symptoms are nasal congestion (resulting in obstruction), and nasal discharge. The solutions proposed are intended for topical intranasal use in newborn, infants, young and older children, and adults. The main ingredients concentration will vary according to the patient's age, effects and side effects observed during the studies. The main ingredient of these solutions is the steroid, Bethamethasone or Dexamethasone. These can be used alone or in combination with an Aminoglycoside antibiotic (Tobramycin or Gentamycin) and/or an anticholinergic agent, such as Ipatropium bromide. The steroid will act as an anti-inflammatory agent and as such, will relieve nasal edema, congestion and obstruction. The anticholinergic agent will decrease nasal discharge through the parasympathetic nervous system. The antibiotic used may act on the nasal bacterial flora and its interaction with an infected, damaged nasal mucosa.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Topical solutions for the treatment of nasal symptoms in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topical solutions for the treatment of nasal symptoms in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical solutions for the treatment of nasal symptoms in the... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1373689

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.